Biosimilars

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

Overview of the Regulatory Framework and FDA’s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US

April 3, 2018

In this on-demand webinar, Sue Lim, MD provides an overview of the background, terminology and general requirements for biosimilar and interchangeable product applications.

The Development and Approval of Inflectra, a Biosimilar to Remicade: Case Presentation

April 3, 2018

In this on-demand webinar, Sue Lim, MD of the FDA provides a general review of the requirements for a biosimilar 351(k) application and discusses the approval process for Inflectra.

APPs: Enhance your delivery of patient care

March 28, 2018

AGA's popular course for advanced practice providers will be held this summer in Chicago.

CMS announces infliximab biosimilar coding changes

March 26, 2018

Effective April 1, codes are available to identify specific versions of the biosimilar administered.

Talking With Your IBD Patients About Biosimilars

Dec. 20, 2017

In this on-demand video series, Sophie Balzora, MD, will provide an overview of the concerns patients may have about biosimilar therapies, and how best to address those concerns.
Advertisement

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.

Get Your Questions Answered on Biosimilar Therapies

Dec. 7, 2017

Join inflammatory bowel disease (IBD) experts on Dec. 11, 2017, 8-8:45 p.m. ET, for a free webinar on biosimilar therapies.

Can You Explain Biosimilars to Patients?

Oct. 25, 2017

AGA is taking the lead in educating health care professionals and their patients about biosimilars and how they can play a role in IBD patient care.

Considerations in Use of Biosimilars for Gastrointestinal Disorders

July 19, 2017

Considerations in Use of Biosimilars for Gastrointestinal Disorders

Advent of Biosimilar Products in US GI Practice

July 19, 2017

Advent of Biosimilar Products in US GI Practice

AGA Makes Six Recommendations to FDA on Interchangeable Biosimilars

May 25, 2017

AGA provides guidance to FDA to ensure patient safety and empower physicians.

DDW® Symposium Will Focus on Biosimilars

May 3, 2017

AGA and the Crohn’s and Colitis Foundation will co-host a DDW Symposium on Biosimilars on Tuesday, May 9, from 2 to 3:30 p.m.

Biosimilars in IBD: The Outlook in 2017

March 6, 2017

Concerns around biosimilars are discussed in this AGA-MedPage Today Reading Room article, including extrapolation and interchangeability.